DK1248618T3 - Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl - Google Patents

Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Info

Publication number
DK1248618T3
DK1248618T3 DK00980817T DK00980817T DK1248618T3 DK 1248618 T3 DK1248618 T3 DK 1248618T3 DK 00980817 T DK00980817 T DK 00980817T DK 00980817 T DK00980817 T DK 00980817T DK 1248618 T3 DK1248618 T3 DK 1248618T3
Authority
DK
Denmark
Prior art keywords
polymorphic
amorphous
methanesulfonylphenyl
bipyridinyl
chloro
Prior art date
Application number
DK00980817T
Other languages
English (en)
Inventor
James A Mccauley
Richard D Tillyer
Sophie Dorothee Clas
Paul O'shea
Chad Dalton
Louis S Crocker
Ian Davies
Original Assignee
Merck Frosst Canada Inc
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc, Merck & Co Inc filed Critical Merck Frosst Canada Inc
Application granted granted Critical
Publication of DK1248618T3 publication Critical patent/DK1248618T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DK00980817T 1999-11-29 2000-11-27 Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl DK1248618T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29

Publications (1)

Publication Number Publication Date
DK1248618T3 true DK1248618T3 (da) 2006-07-10

Family

ID=22609368

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00980817T DK1248618T3 (da) 1999-11-29 2000-11-27 Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Country Status (11)

Country Link
US (3) US6441002B1 (da)
EP (1) EP1248618B1 (da)
JP (1) JP4425514B2 (da)
AT (1) ATE320809T1 (da)
AU (1) AU776544B2 (da)
CA (1) CA2391650C (da)
DE (1) DE60026877T2 (da)
DK (1) DK1248618T3 (da)
ES (1) ES2259295T3 (da)
PT (1) PT1248618E (da)
WO (1) WO2001037833A1 (da)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
PT2479166E (pt) 2009-02-27 2014-11-28 Cadila Healthcare Ltd Processo para a preparação de etoricoxib
EA023286B1 (ru) * 2011-05-27 2016-05-31 ФАРМА ДжРС, Д.О.О. Способ получения полиморфной формы i эторикоксиба
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
EP2831045A2 (en) * 2012-03-30 2015-02-04 Mylan Laboratories, Limited An improved process for the preparation of etoricoxib
WO2014041558A2 (en) 2012-08-27 2014-03-20 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN111410629A (zh) * 2020-03-31 2020-07-14 天津大学 依托考昔溶剂化物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
SI0912518T1 (en) 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
AU759469B2 (en) * 1998-04-24 2003-04-17 Merck Sharp & Dohme Corp. Process for synthesizing cox-2 inhibitors
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis

Also Published As

Publication number Publication date
PT1248618E (pt) 2006-07-31
JP2003514859A (ja) 2003-04-22
CA2391650C (en) 2011-01-25
EP1248618A1 (en) 2002-10-16
AU776544B2 (en) 2004-09-16
EP1248618A4 (en) 2003-05-14
DE60026877D1 (de) 2006-05-11
AU1803101A (en) 2001-06-04
EP1248618B1 (en) 2006-03-22
ES2259295T3 (es) 2006-10-01
JP4425514B2 (ja) 2010-03-03
US6441002B1 (en) 2002-08-27
DE60026877T2 (de) 2006-11-23
US20020198238A1 (en) 2002-12-26
ATE320809T1 (de) 2006-04-15
WO2001037833A1 (en) 2001-05-31
CA2391650A1 (en) 2001-05-31
US20030144327A1 (en) 2003-07-31

Similar Documents

Publication Publication Date Title
DK1248618T3 (da) Polymorfe, amorfe og hydratiserede former af 5-chlor-3-(4-methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
AU2002219322A1 (en) Closed loop fluid-handing system for well drilling
ID19602A (id) Piridin tersubstitusi sebagai inhibitor selektif siklooksigenase-2
DE69906311D1 (de) Diarylbenzopyranderivate als cyclooxygenase-2-inhibitoren
AU2001294009A1 (en) Methods of providing java tamperproofing
YU5503A (sh) Nesteroidni supresori zapaljenja
NO20072142L (no) Mellomprodukter for fremstilling av heterocyklylalkylpiperidinderivater og forbindelser for fremstilling av disse
AU2002352359A1 (en) Method for joining tubulars by expansion
AU2002214505A1 (en) New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
NO20020221D0 (no) Fremgangsmåte for isolasjon av borehull
WO2001030781A3 (en) INHIBITORS OF αLβ2 MEDIATED CELL ADHESION
IS6630A (is) 5-klór-3-(4-metansúlfónýlfenýl)-6'-metýl-[2,3']bípýridinýl á hreinu kristallaformi og aðferð til smíði þess
NO20011436D0 (no) 2,2,6,6-dietyl-dimetyl-1-alkoksy-piperidin-forbindelser og deres korresponderende 1-oksider
NO20032332L (no) Benzodiazepinderivatforbindelser, fremgangsmåte til fremstilling og anvendelse derav
AU2002356533A1 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
WO2000005214A3 (en) Isoquinolines as urokinase inhibitors
AU2001288092A1 (en) Method of crystallization
NO990914L (no) Amorfe benzotiofener, fremgangsmÕter for fremstilling og fremgangsmÕter for anvendelse
DZ3356A1 (en) Novel polymorph v of torasemide.
AU2001285388A1 (en) Open loop timing control for synchronous cdma systems
PT1073438E (pt) Composicoes orais de 8-cloro-6,11-dihidro-11-(4-piperidilidina)-5h-benzo¬5,6|ciclohepta¬1,2-b|piridina
AU2001294408A1 (en) Method for erecting a building, block and dowel therefore
AU7957000A (en) Cyclooxygenase-2 expression inhibitors
NO20011665L (no) Avviksboringssystem
NO20000290L (no) Isolasjonssystem, fremgangsmåte for isolering og anvendelse av isolasjonssystem